1
/
of
0
FDA Drug Approval, N210237, DOLUTEGRAVIR;EMTRICITABINE;TENOFOVIR ALAFENAMIDE
FDA Drug Approval, N210237, DOLUTEGRAVIR;EMTRICITABINE;TENOFOVIR ALAFENAMIDE
Regular price
$149.00 USD
Regular price
Sale price
$149.00 USD
Unit price
/
per
NDA: 210237
Company: MYLAN LABS
Drug Name: DOLUTEGRAVIR;EMTRICITABINE;TENOFOVIR ALAFENAMIDE
Active Ingredients: DOLUTEGRAVIR;EMTRICITABINE;TENOFOVIR ALAFENAMIDE
Strength: 50MG;200MG;25MG
Dosage Form/Route: TABLET;ORAL
Action Date: 02/09/2018
Marketing Status: None (Tentative Approval)
Submission Classification: Type 4 - New Combination
Company: MYLAN LABS
Drug Name: DOLUTEGRAVIR;EMTRICITABINE;TENOFOVIR ALAFENAMIDE
Active Ingredients: DOLUTEGRAVIR;EMTRICITABINE;TENOFOVIR ALAFENAMIDE
Strength: 50MG;200MG;25MG
Dosage Form/Route: TABLET;ORAL
Action Date: 02/09/2018
Marketing Status: None (Tentative Approval)
Submission Classification: Type 4 - New Combination
Couldn't load pickup availability
- Status: Pending Fast-Track Request
- Delivery: Approximately 1 to 2 weeks
NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.
View full details